well IMO (as a long term holder) these short term fluctuations will not matter in the long term so am hanging tight. what will matter is if the company can get moving on other projects - there has always been an urgency there which i don't think was quite got by some. at this point in time the FDA review will be enough to semi-spook an investor but from my reading of articles posted on this thread it may not be as bad an issue as first thought (fingers still crossed though). However by dumping shares that will as yogistone states fall into their hands. some reports are obvious at what is intended. the number of shorters in ACR for some time needed a SP fall to pay the piper and unfortunately the timing of this all was convenient. - all IMO so DYOR. Wonder if ASIC keeps tabs of this shorting issue that generall plagues the market?
ACR Price at posting:
$2.06 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)